2023. Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: Absolute PASI Outcomes Over 52 Weeks in the Phase 3 POETYK PSO-1 Trial. SKIN The Journal of Cutaneous Medicine. 7, 6 (Nov. 2023), s239. DOI:https://doi.org/10.25251/skin.7.supp.239.